Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Punch biopsy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    69 result(s) found for: Punch biopsy. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2015-004494-33 Sponsor Protocol Number: 2015-004494-33 Start Date*: 2016-01-20
    Sponsor Name:Herlev and Gentofte Hospital
    Full Title: Anti-IL-17, a possible new treatment for contact dermatitis?
    Medical condition: allergic contact dermatitis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10056265 Allergic contact dermatitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-002179-12 Sponsor Protocol Number: PRILODE50-FUSION Start Date*: 2022-09-16
    Sponsor Name:Matilde Zaballos
    Full Title: Determination of the effective dose 50 of intrathecal hyperbaric prilocaine required for the transrectal ultrasound guidance fusion-targeted prostate biopsy in ambulatory surgery
    Medical condition: anaesthesia for prostate fusion biopsy in outpatient surgery
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10004825 Biopsy of prostate LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003740-39 Sponsor Protocol Number: URO-CHUAC-BPSat-001. Start Date*: 2016-04-12
    Sponsor Name:Jose Luis Ponce Díaz-Reixa
    Full Title: Open randomized clinical trial to examine individual pain tolerance in the use of two anesthetic techniques to perform saturation prostate biopsy .
    Medical condition: Prostate biopsy anesthesia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004848 10004825 Biopsy of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-018191-34 Sponsor Protocol Number: FOL003 Start Date*: 2010-07-21
    Sponsor Name:Follica Inc.
    Full Title: A Study to Explore the Effect of Controlled Cutaneous Perturbation and Pharmacologic Modulation for Inducing Follicular Neogenesis
    Medical condition: Male subjects with androgenetic alopecia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10068168 Androgenetic alopecia LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005592-12 Sponsor Protocol Number: 76873 Start Date*: 2021-08-30
    Sponsor Name:Plastikkirurgisk og brystkirurgisk afdeling, Region Sjælland
    Full Title: The effect of tranexamic acid on seroma formation after mastectomies
    Medical condition: Immunomodulation of postoperative inflammatory reactions and thereby reduction of wound seroma by topical administration of tranexamic acid.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10002784 Antifibrinolysis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001381-38 Sponsor Protocol Number: 1 Start Date*: 2021-08-30
    Sponsor Name:Plastikkirurgisk og brystkirurgisk afdeling, Region Sjælland
    Full Title: Topical use of tranexamic acid for optimisation of wound healing in a novel, acute wound model
    Medical condition: Immunomodulation of postoperative inflammatory reactions and thereby reduction of wound fluid production and improved healing by topical administration of tranexamic acid.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10002784 Antifibrinolysis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002545-38 Sponsor Protocol Number: 68943 Start Date*: 2019-09-13
    Sponsor Name:Bispebjerg Hospital, Department of Dermatology
    Full Title: Biodistribution of ablative fractional laser-assisted topical delivery of Vismodegib in basal cell carcinomas.
    Medical condition: Basal cell carcinoma Simple nodular basal cell carcinoma at any body locations
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066495 Basal cell carcinoma recurrent LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073093 Nodular basal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-002554-78 Sponsor Protocol Number: PB-102-F02 Start Date*: 2013-08-29
    Sponsor Name:Protalix Ltd.
    Full Title: An Extension of Phase 1/2, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion ...
    Medical condition: Fabry disease
    Disease: Version SOC Term Classification Code Term Level
    16.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-001458-10 Sponsor Protocol Number: RN1002-0028 Start Date*: 2004-12-21
    Sponsor Name:Renovo Ltd
    Full Title: A single site, placebo and standard-care controlled, double blind, randomised trial to investigate the efficacy of four doses of RN1002 in accelerating early wound healing of punch biopsy wounds
    Medical condition: Wound Healing
    Disease: Version SOC Term Classification Code Term Level
    1.1 10036892 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000946-37 Sponsor Protocol Number: R668-AD-1121 Start Date*: 2012-06-13
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A randomized, double-blind, parallel-group, placebo-controlled study to assess the safety of REGN668 administered concomitantly with topical corticosteroids to patients with moderate-to-severe Atop...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005809-77 Sponsor Protocol Number: NL38217 Start Date*: 2013-01-31
    Sponsor Name:Maastricht University Medical Centre
    Full Title: Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5-aminolevulinic acid 20% versus two stage topical photodynamic therapy with methylaminolevulinate
    Medical condition: Superficial basal cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000486-72 Sponsor Protocol Number: ALA-AK-CT010 Start Date*: 2017-07-28
    Sponsor Name:Biofrontera Bioscience GmbH
    Full Title: A randomized, double-blind, intra-individual, multi-center phase III study to evaluate the safety and efficacy of BF 200 ALA (Ameluz®) versus placebo in the treatment of mild to severe actinic kera...
    Medical condition: Actinic keratosis (AK)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002678-11 Sponsor Protocol Number: ICO-13-001 Start Date*: 2018-06-07
    Sponsor Name:Institut Català d’Oncologia
    Full Title: An open label biomarker pilot study of the antitumoral acrivity of denosumab in the pre-operative setting of early breast cancer
    Medical condition: early breast cancer
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-000864-42 Sponsor Protocol Number: IFX-1-P2.8 Start Date*: 2021-04-27
    Sponsor Name:InflaRx GmbH
    Full Title: OPEN LABEL, MULTICENTER PHASE II STUDY OF THE C5A-ANTIBODY IFX-1 ALONE OR IFX-1 + PEMBROLIZUMAB IN PATIENTS WITH PD-1- OR PD-L1-RESISTANT/REFRACTORY LOCALLY ADVANCED OR METASTATIC CUTANEOUS SQUAMOU...
    Medical condition: Locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041823 Squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002856-26 Sponsor Protocol Number: ADO-EP02(ML29328) Start Date*: 2016-12-19
    Sponsor Name:SRH Wald-Klinikum Gera GmbH
    Full Title: A PHASE II, SINGLE-ARMED, MULTICENTER TRIAL OF NEOADJUVANT VISMODEGIB IN PATIENTS WITH LARGE AND/OR RECURRENT RESECTABLE BASAL CELL CARCINOMA
    Medical condition: Patients with large and/or recurrent resectable basal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002672-40 Sponsor Protocol Number: SGNTUC-029 Start Date*: 2022-09-20
    Sponsor Name:Seagen Inc.
    Full Title: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Su...
    Medical condition: unresectable or metastatic HER2+ colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) SK (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) IE (Trial now transitioned) PT (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) AT (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002991-15 Sponsor Protocol Number: SOLTI-1804 Start Date*: 2019-11-04
    Sponsor Name:SOLTI
    Full Title: HER2-PREDICT: Estudio Traslacional De Muestras De Tumor Procedentes De Los Ensayos Ds8201-A-U301 y Ds8201-A-U302
    Medical condition: Her2‑positive, unresectable and/or metastatic breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002299-41 Sponsor Protocol Number: KY1005-CT02 Start Date*: 2019-01-24
    Sponsor Name:Kymab Limited
    Full Title: A Phase IIa, Randomised, Double Blind, Placebo Controlled, Parallel Group, Multicentre Study of an Anti OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-000197-30 Sponsor Protocol Number: UoL001289 Start Date*: 2018-07-13
    Sponsor Name:The University of Liverpool
    Full Title: Sodium Valproate for Epigenetic Reprogramming in the Management of High Risk Oral Epithelial Dysplasia
    Medical condition: High Risk Oral Epithelial Dysplasia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-004746-17 Sponsor Protocol Number: 17HH4283 Start Date*: 2018-03-05
    Sponsor Name:Joint Research Compliance Office, Imperial College London and Imperial College Healthcare NHS Trust
    Full Title: Pain relief with disease modification by Capsaicin 8% patch: a clinical study in Diabetic Peripheral Neuropathy
    Medical condition: Diabetic painful neuropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 11:34:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA